388 related articles for article (PubMed ID: 23494602)
21. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
25. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
26. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Fox EJ; Sullivan HC; Gazda SK; Mayer L; O'Donnell L; Melia K; Lake SL
Eur J Neurol; 2012 Feb; 19(2):307-11. PubMed ID: 21899662
[TBL] [Abstract][Full Text] [Related]
27. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
28. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
29. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
30. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
32. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
[TBL] [Abstract][Full Text] [Related]
38. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
39. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]